Segal Trials is honored to have contributed significantly to the FDA approval of COBENFYtm (xanomeline and trospium chloride), a groundbreaking first-in-class muscarinic agonist developed by Bristol ...
Segal Trials contributed to the FDA approval of COBENFY™, a new schizophrenia treatment, highlighting their role in advancing ...
Hosted on MSN3h
Bristol Myers Raises Profit Forecast on Drug Demand(Bloomberg) -- Bristol Myers Squibb Co. raised its 2024 profit forecast as demand ... The anti-inflammatory Sotyktu, the heart drug Camzyos, and the anemia treatment Reblozyl — three drugs on which ...
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
FARGO — A new FDA approved drug, to help people with schizophrenia, will soon be accessible for medical officials to ...
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback